Caribou Biosciences Inc (nasdaq:CRBU) Share Price

Company Profile

Business description
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
Contact
2929 7th Street
Suite 105
BerkeleyCA94710
USA
T: +1 510 982-6030
https://www.cariboubio.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
97

Recommended

Amid robust demand for semis, watch for any impact of in-house built chips and whether the supply chain is on track.

Brian Colello, CPA | 12 May 2026

Interest rates are driving a spike in property listings.

Roy Van Keulen | 12 May 2026

With uncertainty regarding its total addressable market and competitive threats, here’s what we think of Palantir stock.

Mark Giarelli | 12 May 2026

Index	Last price	Change	% Change
All Ordinaries	8,868.30	4.70	-0.05%
CAC 40	7,979.92	76.46	-0.95%
DAX 40	23,954.93	395.35	-1.62%
Dow JONES (US)	49,760.56	56.09	0.11%
FTSE 100	10,265.32	4.11	-0.04%
HKSE	26,347.91	58.93	-0.22%
NASDAQ	26,088.20	185.92	-0.71%
Nikkei 225	62,520.11	222.46	-0.35%
NZX 50 Index	13,043.10	37.23	-0.28%
S&P 500	7,400.96	11.88	-0.16%
S&P/ASX 200	8,624.50	6.50	-0.08%
SSE Composite Index	4,214.49	10.53	-0.25%